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Abstract
Summary Higher physiologic testosterone levels among
community dwelling older men and women may protect
against falls, and this benefit may be further increased
among those taking additional vitamin D plus calcium.
Introduction The aim of this study is to investigate sex
hormone levels and fall risk in older men and women.
Methods One hundred and ninety-nine men and 246
women age 65+ living at home were followed for 3 years
after baseline assessment of sex hormones. Analyses
controlled for several covariates, including baseline 25-
hydroxyvitamin D, sex hormone binding globulin, and
vitamin D plus calcium treatment (vitD+cal).
Results Compared to the lowest quartile, men and women
in the highest quartile of total testosterone had a decreased
odds of falling (men: OR=0.22; 95% CI [0.07,0.72]/
women: OR=0.34; 95% CI [0.14,0.83]); if those individ-
uals also took vitD+cal, the fall reduction was enhanced
(men: OR=0.16; 95% CI [0.03,0.90] / women: OR=0.15;
95% CI [0.04,0.57]). Similarly, women in the top quartile
of dihydroepiandrosterone sulfate (DHEA-S) had a lower
risk of falling (OR=0.39; 95% CI [0.16,0.93]). Other sex
hormones and SHBG did not predict falling in men or
women.
Conclusions Higher testosterone levels in both genders and
higher DHEA-S levels in women predicted a more than 60%
lower risk of falling. With vitD+cal, the anti-fall benefit of
higher physiologic testosterone levels is enhanced from 78%
to 84% among men and from 66% to 85% among women.
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Introduction
An inverse association between sex hormone levels and hip
fracture risk has been documented [1], explained by
benefits on bone remodeling [2] and bone density [3, 4].
Additionally, lower sex hormone levels may be associated
with increased fall risk as an alternative pathway explaining
elevated hip fracture risk with age. Given that falling is a
primary risk factor of hip fracture among older individuals,
factors that relate to falling need careful evaluation,
especially if deficiencies are amendable to treatment.
Testosterone levels decline with age in both men and
women [5], and testosterone replacement may increase lean
body mass [6] and muscle strength [7] in men with low
testosterone levels. Among healthy older men with normal
to mildly decreased testosterone levels, testosterone sup-
plementation increased lean body mass [6–9], although
strength and functional performance were unchanged with
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testosterone replacement in some studies performed in men
age 65 and older [7, 10]. Regarding fall risk and
testosterone levels, observational studies have been incon-
sistent with an inverse association documented in one [11]
of two prospective studies [12] among older men. Whether
higher testosterone levels reduce fall risk among women,
where levels of the hormone are far lower, is unclear [4, 12].
Bioavailable and free estradiol levels decline with age in
men and women [13]. While some studies found that
estrogen therapy may enhance muscle strength in older
women [14, 15], others did not find a benefit [16, 17].
Limited data from one observational study suggested no
association between estrogen levels and muscle strength or
fall risk in older men or women [12].
DHEA-S exerts its action indirectly after its conversion
to androgens and estrogens in peripheral tissues. Its
association with falling among older individuals is unclear
with two observational studies suggesting a positive
correlation of the hormone with muscle strength in older
men and women [18, 19]. Whether sex hormone binding
globulin (SHBG) is associated with falling has not been
explored. However, SHBG may play an important adverse
role in older individuals as it increases with age and
possibly contributes to a decreased bioavailability of sex
hormones [4].
Given the scarcity of studies on the role of sex hormone
levels and the risk of falling in older persons, we assess the
association of baseline sex hormone levels and subsequent
risk of falling over a 3-year follow-up. Taking advantage of
the blinded intervention with vitamin D plus calcium within
this data set, we were able to explore a possible additive
benefit of higher hormone levels and treatment with
vitamin D plus calcium. Vitamin D, similar to testosterone
and estrogen, is a steroid hormone, and previous random-
ized controlled trials suggested a significant improvement
of strength [20] and reduction of falls [21–23] with vitamin
D treatment. In the same data set, vitamin D plus calcium
significantly reduced the odds of falling in women (odds
ratio [OR], 0.54; 95% confidence interval [CI], 0.30–0.97),
but not in men (OR, 0.93; 95% CI, 0.50–1.72) [23]. If there
was an additive benefit, future intervention studies targeting
falls may optimize sex hormone levels and vitamin D plus
calcium intake to decrease fall risk most efficiently. Finally,
we studied the association of sex hormone levels with total
and leg lean body mass.
Methods
Subjects
The Boston Stop-It trial is a 3-year double-blind random-
ized controlled trial on the effect of vitamin D3 (700 IU per
day) plus calcium (500 mg per day) on bone mineral
density and fractures [24]. Of 848 persons who were
prescreened with questionnaires, 545 were invited for
screening. The final study sample was 445 subjects (199
men and 245 women). Apart from DXA measurements and
fractures, falls were assessed throughout the trial, as well as
sex hormone levels at baseline. The latter data were used in
the present analyses. All participants provided written
informed consent and the study protocol was approved by
the Investigation Review Board at Tufts University.
Exclusion criteria
The trial enrolled healthy ambulatory older men and women
age 65 or older living in the community [24]. The trial
excluded individuals with Parkinson's disease or hemiplegia,
cancer or hyperparathyroidism. The criteria of exclusion also
included a kidney stone in the past 5 years, renal disease
(serum creatinine >1.2 mg/dl), liver disease, bilateral hip
surgery, dietary calcium intake exceeding 1500 mg/day,
therapy with testosterone, estrogen, tamoxifen, bisphospho-
nate, fluoride or calcitonin in the past two years.
Follow-up
Of 445 subjects who were randomized, 389 attended the 3-
year follow-up visit and 318 were still on study medication
at the 3-year follow-up visit. For this analysis, we used all
445 individuals randomized.
Fall definition and ascertainment
Falls were ascertained by postcards. Participants were asked
to send a postcard after every fall, which was then followed
by a phone call from a staff member to assess the
circumstances of the fall. In addition, falls were ascertained
at every 6-month follow-up visit.
We included all reported fall events. Falls were defined
as “unintentionally coming to rest on the ground, floor, or
other lower level” [25]. Falls due to severe trauma
involving external force or vehicles were not counted as a
fall. Falling at least once was the primary outcome of the
analyses.
Measurements
Baseline BMI is weight in kilograms divided by height in
meters squared measured at the study center. Physical
activity included leisure, household, and occupational
activity as estimated by the Physical Activity Scale for the
Elderly (PASE) questionnaire [26]. Tobacco use and use of
alcoholic beverages were assessed by a questionnaire at
baseline.
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Comorbid conditions assessed at baseline with a ques-
tionnaire were summarized with a comorbidity score, which
represents the sum of the following comorbid conditions:
diabetes, hyperthyroidism, hypertension, cancer, low back
surgery, previous hip fracture, and stomach surgery.
Total and leg lean body mass was measured by dual-
energy x-ray absorptiometry using a DPX-L scanner (Lunar
Radiation, Madison Wisconsin). The reproducibility of lean
tissue mass measurements was 1.0% [27].
Laboratory investigations
On the baseline visit, venous blood was collected between
7:00 and 9:30 a.m. after the subjects had fasted for at least
8 hours. Plasma 25-OHD levels were measured by
competitive protein binding assay, as described by Preece
et al., with intra- and interassay CVs of 5.6% to 7.7% [28].
All following hormones were measured in the laboratory of
the late Dr. Christopher Longcope at the University of
Massachusetts in Worcester. Estrone and estradiol were
measured in serum by radioimmunoassay following solvent
extraction and celite chromatography. The intra- and inter-
assay CVs for estrone were 5.0 and 10.0% and for estradiol
were 7.0 and 13.2%, respectively. The estradiol assay had a
detection level of 5 to 7 pg/ml. Androstenedione was
measured in serum using radioimmunoassay kits from
Diagnostic System Laboratories (Webster, TX). This anti-
body is highly specific with negligible cross-reaction with
other steroids. The intra- and inter-assay CVs were 7.3%
and 9.8%, respectively. DHEA-S was measured in serum
using radioimmunoassay kits from ICN Biomedical (Costa-
Mesa, CA) with relatively high cross-reactions, 30%–60%,
with dehydroepiandrosterone and androstenedione. Since
DHEA-S circulates at levels at least 1,000 times those of the
other two steroids, this cross-reaction does not interfere with
the assay. The intra- and inter-assay CVs were 4.3% and
8.6%, respectively. Total testosterone was measured in serum
using radioimmunoassay kits from Diagnostic Products Corp
(Los Angeles, CA). There are no significant cross-reactions
with other natural steroids. The intra- and inter-assay CVs
were 5.9% and 8.7%, respectively. Free testosterone was
measured by the method of Hammond et al. [29]. The
measurement was done with centrifugal ultrafiltration and
the inter- and intra-assay CVs are 8.9% and 5.2%,
respectively.
Statistical analysis
We used logistic regression to evaluate the effect of quartiles
of sex hormone levels with the lowest quartile as the
reference on a person’s risk of falling at least once during
the 3-year follow-up. In men and women, all analyses were
controlled for age in years, baseline BMI in kg/m2 (<25, 25–
29, ≥30), baseline plasma 25-OHD levels, baseline PASE
status for physical activity assessment, baseline smoking
status (never, current, former smoker), baseline use of
alcoholic beverages (yes/no), baseline number of comorbid
conditions, treatment with vitamin D plus calcium or
placebo, and length of follow-up in days. The analyses for
total testosterone, estrone and estradiol were also controlled
for SHBG in men and women.
In addition, we compared the baseline mean total lean
body mass and the baseline mean leg lean body mass
among quartiles of baseline sex hormone levels using a
multiple linear regression model while adjusting for age in
years, baseline BMI in kg/m2 (<25, 25–29, ≥30), baseline
plasma 25-OHD levels, baseline PASE, baseline smoking
status (never, current, former smoker), baseline use of
alcoholic beverages (yes/no) and baseline number of
comorbid conditions. Least square means were used to
express the adjusted mean and percent difference in lean
body mass by quartiles of sex hormone levels.
Table 1 Characteristics of the
study population
PASE is the Physical Activity
Score for the Elderly
Characteristic mean±standard deviation Men No.=199 Women No.=247 p-value
Age (yr) 71±5 71±5 0.29
BMI (kg/m2) 27.0±3.4 26.7±4.8 0.44
25-OHD (ng/l) 33.0±14.2 26.6±12.7 <0.0001
Physical activity (PASE) 124±57 106±50 0.003
Ever smokers (percent) 67% 52% 0.004
Alcoholic bev. / day (percent) 74% 65% 0.05
Testosterone (ng/ml) 4.98+1.54 0.37+0.27 <0.0001
Free testosterone (pg/ml) 1.42+0.36 1.04+0.49 <0.0001
SHBG (ng/l) 56.0+22.3 75.1+36.4 <0.0001
DHEA-S (μg/ml) 0.98+0.69 0.60+0.45 <0.0001
Estrone (pg/ml) 29.9+14.0 30.1+18.9 0.87
Estradiol (pg/ml) 28.3+11.2 25.5+16.9 0.04
Androstenedione (ng/ml) 1.28+0.54 1.00+0.55 <0.0001
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All analyses were conducted with SAS (Version 8.2; SAS
Institute Inc., Cary, NC, USA). All p-values were two-sided.
Results
Baseline characteristics by sex are displayed in Table 1.
While mean age was the same for men and women, women
were less physically active, had lower 25-hydroxyvitamin
D levels and were less likely to be ever smokers. Hormone
levels, differed by sex significantly with one exception,
estrone. Overall, 49% (97) of men and 57% (134) of
women fell during the 3-year follow-up.
Risk of falling by hormone levels
Among men, total testosterone levels independent of SHBG
were significantly associated with the odds of falling. Men
in the highest quartile of total testosterone with serum
levels of 5.68 ng/ml or above had a 78% decreased odds of
falling compared to men in the lowest quartile with total
testosterone levels of 3.77 ng/ml or less (OR=0.22; 95% CI
[0.07,0.72]). There was a significant trend between a lower
odds of falling and higher total testosterone levels (p=
0.005). See Fig. 1 for exact boundaries of quartiles and
illustration of the observed trend.
Among women, similar to men, there was a significant
trend between a lower odds of falling and higher testosterone
levels (p=0.03). Women in the top quartile of testosterone
with serum levels of 0.49 ng/ml and above had a 66%
decreased risk of falling compared to those in the lowest
quartile with serum levels of 0.20 ng/ml or less (OR=0.34;
95% CI [0.14,0.83]). See Fig. 1 for exact boundaries of
quartiles and illustration of the observed trend.
Also, women in the top quartile of DHEA-S had a 61%
lower risk of falling compared to those in the lowest
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Fig. 1 Odds of falling by quartile of total testosterone in men and in
women. Independent of age, body mass index, physical activity,
SHBG levels, 25(OH)D levels, vitamin D plus calcium treatment,
number of comorbid conditions, smoking and alcohol consumption,
there was a significant trend in men (test for trend: p=0.005) and
women (test for trend: p=0.03) suggesting a decrease in the odds of
falling with higher testosterone levels. In a comparison of the two
extreme quartiles, men in the highest quartile had a 78% and women
had a 66% lower odds of falling. Results were similar with or without
adjustment for SHBG
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quartile (OR=0.39; 95% CI [0.16,0.93] (see Table 2). There
appeared to be a threshold effect with a benefit in all
women reaching serum levels of above 0.30 μg/ml, the
upper end of the lowest quartile. Among men, there was a
similar directionality with a decreased risk of falling with
higher DHEA-S levels. However, this was not significant.
Estrone, estradiol, free testosterone, androstenedione,
and SHBG were not significantly associated with the odds
of falling.
As this was a double-blind RCT with vitamin D plus
calcium compared to placebo [23], we were able to explore a
possible additive benefit of higher testosterone levels and
vitamin D plus calcium supplementation on fall prevention in
Table 3. Among men and women, there was an additional
benefit of being in the sex-specific top quartile of serum
testosterone plus being randomized to vitamin D and calcium.
Hormone levels and lean body mass
There was a significant inverse association between
baseline total and leg lean body mass, and quartiles of
SHBG in both men and women (see adjusted means in
Fig. 2a and b). All sex hormones were not appreciably
associated with lean body mass.
Table 2 Odds of falling across quartiles of estradiol, DHEA-S, and SHBG
Range of top and lowest quartile by sex Effect men OR [95% CI] p-value for trend Effect women OR [95% CI] p-value for trend
Estradiol (pg/ml)
Men bottom <17 – Reference
Men second 18.0–24.0 0.42 [0.16,1.16]
Men third 25.0–31.0 0.63 [0.24,1.65]
Men top >31.0 0.88 [0.35–2.23]
*p=0.98
Women bottom ≤14 – Reference
Women second 15.0–21.0 1.79 [0.75–4.22]
Women third 22.0–30.0 1.36 [0.59–3.13]
Women top >30.0 0.92 [0.40–2.13]
*p=0.76
DHEA-S (μg/ml)
Men bottom ≤0.53 – Reference
Men second 0.54–0.78 0.90 [0.33,2.44]
Men third 0.79–1.20 0.49 [0.18,1.31]
Men top >1.20 0.56 [0.21–1.46]
*p=0.14
Women bottom ≤0.30 – Reference
Women second 0.31–0.45 0.27 [0.11,0.63]**
Women third 0.46–0.75 0.43 [0.18,1.02]
Women top >0.75 0.39 [0.16–0.93]**
*p=0.08
SHBG (ng/ml)
Men bottom ≤41.05 – Reference
Men second 41.06–52.93 2.86 [1.08,7.54]**
Men third 52.94–65.46 0.98 [0.38,2.54]
Men top >65.46 1.54 [0.57–4.14]
*p=0.89
Women bottom ≤51.53 – Reference
Women second 51.54–65.08 0.66 [0.27,1.60]
Women third 65.09–90.25 1.21 [0.49,2.95]
Women top >90.25 0.57 [0.22–1.41]
*p=0.47
All analyses controlled for age, baseline BMI, baseline plasma 25-OHD levels, baseline PASE status for physical activity assessment, baseline
smoking status, baseline use of alcoholic beverages, baseline number of comorbid conditions, treatment with vitamin D plus calcium or placebo,
and length of follow-up in days. Similar to estrone, there was no significant association between the odds of falling and estradiol and
androstenedione levels
*p-value for trend test. **Significantly different from reference
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Discussion
We found that fall risk declines with higher physiological
testosterone levels among older ambulatory men and
women independent of age, SHBG levels, body mass
index, physical activity, smoking, alcohol consumption,
number of comorbid conditions, vitamin D plus calcium
treatment, and length of follow-up. Men and women in the
top quartile of sex specific testosterone levels had a 78%
respectively 66% lower risk of falling compared to
individuals in the lowest quartile. This benefit was
augmented if individuals in the top quartile had additional
vitamin D plus calcium supplementation. In this subgroup
fall risk was reduced by 84% in men and 85% in women.
The additional benefit of vitamin D plus calcium may be
explained by evidence from several randomized controlled
trials showing that vitamin D supplementation reduces the
risk of falls in older individuals by enhancing muscle
strength and balance [20, 21, 23, 30, 31]. From a clinical
perspective the possible additive benefit of higher physio-
logic testosterone levels and vitamin D plus calcium
supplementation is of interest as the additional benefit
appears to be significant, applies to both sexes, and both
components can be altered by treatment. In fact, in our
earlier analyses of the RCT, which did not take testosterone
levels into consideration, vitamin D plus calcium reduced
falls among women (OR=0.54; 95% confidence interval
[CI], 0.30–0.97), but not in men (OR=0.93; 95% CI, 0.50–
1.72) compared to placebo [23]. Thus, especially among
men, the additional correction of testosterone levels to the
upper end of the physiologic range may be important.
There was no association between estrogen levels and
falls in either sex. Our findings are consistent with two
prospective cohort studies, which did not find an associa-
tion between estrogen levels and incident falls among older
men [11, 12] or women [12]. Furthermore, one double-
blind randomized controlled trial with falls as the outcome
did not find a protective effect of hormone replacement
therapy in ambulatory older women [32]. Thus, in contrast
to the previously documented benefit of estrogen on bone
density in men [33] and women [34], higher estrogen levels
may not protect from falls in either sex.
We found that higher DHEA-S levels may reduce the
odds of falling by 61% in women and there appeared to be
a similar direction in men. Our study adds to the literature
suggesting that higher physiological levels, above 0.31 μg/l,
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Fig. 2 a Adjusted mean baseline leg. b Total body lean mass by
quartiles of baseline SHBG. Mean adjusted lean mass by quartiles of
SHBG is adjusted for age, physical activity, 25(OH)D levels, number
of comorbid conditions, smoking and alcohol consumption. P-values
for comparison of quartiles with reference quartile (bottom quartile for
SHBG): *<0.05, **<0.001. Among men, the test for trend was
significant for total body (p=0.005) and leg (0.03) lean mass. Among
women, the test for trend was significant among women for total body
(p=0.005) and leg (p=0.0002) lean mass
Table 3 Effect of higher testosterone levels on falling by vitamin D + calcium supplementation
Sex-specific total testosterone quartiles Results adjusted for treatment
OR [95% CI]
Results in placebo group
OR [95% CI]
Results in vitamin D + calcium
group OR [95% CI]
Men
Comparing top to bottom quartile 0.22 [0.07, 0.72] 0.23 [0.04, 1.40] 0.16 [0.03, 0.90]
Women
Comparing top to bottom quartile 0.34 [0.14, 0.83] 0.41 [0.09, 1.86] 0.15 [0.04, 0.57]
All analyses controlled for age, baseline BMI, baseline plasma 25-OHD levels, baseline PASE status for physical activity assessment, baseline smoking
status, baseline use of alcoholic beverages, baseline number of comorbid conditions, and length of follow-up in days. Our data suggest an additive
benefit of high testosterone levels and vitamin D (700 IU per day) plus calcium (500 mg per day) supplementation in older men and women
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may be beneficial for fall prevention in women. Additional
data are needed in both men and women.
There was no association of the directly measured free
testosterone on falls in both genders. Physiologically, it is
expected that free testosterone reflects the bioavailable part
of total testosterone that enters the cells and is most
sensitive to outcomes, such as falls. However, it has been
suggested that measurement of free testosterone may
present with difficulties or may not best represent the
bioavailable fraction of testosterone [35]. Alternatively, we
controlled for SHBG when assessing the benefits of
testosterone, which may approximates the truly bioavailable
fraction of testosterone. Androstenedione levels and SHBG
levels were not associated with falling in men or women.
Only SHBG showed a significant inverse association
with total and leg lean body mass in men and women.
Specifically, based on our adjusted results, men in the top
quartile of serum SHBG concentrations had a 6% lower leg
lean mass and women in the top quartile had a 9% lower
leg lean mass. Higher SHGB levels have previously been
identified as a risk factor for hip fractures in the Study of
Osteoporotic Fracture (SOF) [36]. Our results support these
findings indirectly, as low leg lean body mass is a correlate
of quadriceps weakness [37] and poor structural parameters
of bone [38], which are risk factors for hip fractures [37].
However, leg lean mass is a surrogate of muscle force with
limitations and direct strength measures are preferable if the
target endpoint is falling. Mechanistically, a higher protein
intake may decrease SHBG levels resulting in a higher lean
body mass. In the Massachusetts Male Aging Study, protein
intake showed a negative association with SHBG levels [39].
Despite its protective role in regard to falls, there was no
association between baseline total testosterone levels and
baseline total or leg lean body mass. One explanation may
be that the effect was too small to be picked up cross-
sectionally or that the physiologic range did not provide
large enough contrasts. Previous studies on testosterone
replacement among hypogonadal men found a significant
increase in lean body mass [6] and muscle strength [7].
Also, three cohort studies documented a significant associ-
ation between lower testosterone levels and risk of
sarcopenia [40], reduced physical performance or reduced
muscle strength [11, 12].
In summary, higher physiological testosterone levels
may be advantageous for fall prevention in older men and
women. Fall prevention may be further improved by
providing vitamin D plus calcium supplementation to
individuals with higher physiologic testosterone levels.
Future intervention studies are needed to test the effect of
testosterone supplementation on falls in combination with
vitamin D and calcium supplementation. These studies may
aim to bring older men and women up to the upper
reference range for sex-specific physiologic testosterone
levels, as this may be sufficient for fall prevention
according to our results. The combined benefit of higher
testosterone and vitamin D plus calcium appears to be
additive.
Based on our cross-sectional findings, body composition
is not associated with sex hormones but SHBG levels. Lean
mass was highest among men and women with low SHBG
levels. Thus, factors that impact on SHBG status may need
further exploration.
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